Skip to content
Clinical Trials – home
Therapeutic area

Nervous system disorders – page 99

  • 1 397 clinical trials
  • 586 recruiting
  • 459 conditions
  • 29 countries

Conditions in this area

459 conditions with trials, the busiest first

Clinical trials in Nervous system disorders

1 397 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 397 clinical trials

Partial seizures

Not recruiting

Study on the Safety and Effectiveness of Cenobamate for Children with Focal Seizures

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cenobamate
  • Sponsor:Sk Life Science Inc.

Study of Eliglustat alone or with imiglucerase in children and adolescents aged 2-17 years with Gaucher disease type 1 and type 3

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Eliglustat Tartrate
  • Sponsor:Genzyme Corp.

Ataxia telangiectasia

Not recruiting

Study on the Effects of EryDex (Dexamethasone Sodium Phosphate) for Children Aged 6-9 with Ataxia Telangiectasia

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Quince Therapeutics S.p.A.

Ischaemic stroke

Not recruiting

Study on Tirofiban and Aspirin for Patients with Acute Ischemic Stroke Due to Tandem Lesion

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Study on the Effects of Atidarsagene Autotemcel for Patients with Late Juvenile Metachromatic Leukodystrophy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Atidarsagene Autotemcel
  • Sponsor:Orchard Therapeutics (Europe) Limited
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Resamirigene Bilparvovec
  • Sponsor:Astellas Gene Therapies Inc.

Study Comparing Human Normal Immunoglobulin and Placebo for Children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Human Normal Immunoglobulin
  • Sponsor:Octapharma Pharmazeutika Produktionsgesellschaft mbH

Fragile X syndrome

Not recruiting

Study on Long-Term Safety of ZYN002 Gel for Children, Adolescents, and Young Adults with Fragile X Syndrome

InvestigationalNo placebo
Countries:IrelandIreland
  • Participants:0–17 years · 18–64 years
  • Substances:Cannabidiol
  • Sponsor:Harmony Biosciences Management Inc.

Epilepsy

Not recruiting

Study on the Effectiveness and Safety of Perampanel for Children with Epilepsy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Perampanel
  • Sponsor:Eisai Limited

Huntington's disease

Not recruiting

Study on the Safety and Effects of PTC518 for Patients with Huntington's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:PTC518
  • Sponsor:PTC Therapeutics Inc.

Cerebral palsy+1

Not recruiting

Study on the Effectiveness and Safety of NT 201 for Treating Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy

Registered drug
Countries:LatviaLatvia
  • Participants:0–17 years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Merz Pharmaceuticals GmbH

Neuroblastoma

Not recruiting

Study on Dinutuximab Beta and Chemotherapy for Patients with Neuroblastoma Resistant to Standard Treatment or with Relapsed Disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Dinutuximab Beta
  • Sponsor:Uniwersytet Jagiellonski Collegium Medicum

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.